Dr. Reddy's Laboratories Ltd. on Thursday said it has acquired the STUGERON® brand portfolio from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, for $50.5 million. The definitive transaction, announced Thursday, gives Dr. Reddy's access to Stugeron and its related brands, including Stugeron Forte and Stugeron Plus, across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, with India and Vietnam as key markets.
The acquisition is a strategic move to strengthen Dr. Reddy's Central Nervous System (CNS) portfolio and expand into the anti-vertigo segment. The company noted that Stugeron already holds the top position in the cinnarizine pharmaceutical market and is ranked second in the anti-vertigo extended pharmaceutical market in India.
Dr. Reddy's stated that the operations of the acquired business will be gradually transitioned to ensure smooth integration. The company's CEO of Branded Markets, M.V. Ramana, said the deal "reflects a steady advancement in our efforts" and aligns with the company's goal of reaching over 1.5 billion patients by 2030.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
